Skip to main content
Equibles
XENE logo

XENE · Xenon Pharmaceuticals Inc. · Earnings Call Transcripts & Audio

Track XENE — free

Use XENE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XENE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$37.19 -0.06 (-0.16%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$3.58B
Shares
96.84M
Volume · Sep 30 2.47M Avg daily vol (3M) 1.41M

Xenon Pharmaceuticals Inc. Earnings Call Transcripts

Quarterly earnings calls for Xenon Pharmaceuticals Inc. (XENE), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼98.4% $132,000 −$37.15M '22 Q3 22-11-08 ▼100% $ −$37.40M '22 Q4 23-03-01 · $ −$47.93M '24 Q1 24-05-09 · $ −$57.92M '24 Q2 24-08-08 · $ −$62.79M '24 Q3 24-11-12 · $ −$65.69M '24 Q4 25-02-27 · $7.50M −$65.05M '25 Q1 25-05-12 · $ −$84.71M '25 Q2 25-08-11 · $ −$90.90M '25 Q3 25-11-03 · $ −$105.26M '25 Q4 26-03-09 ▼100% $ −$102.30M '26 Q1 26-05-07 LATEST · $ −$110.74M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Confident tone AZK NDA submission and launch readiness for focal seizures Pain pipeline (KV7 and Nav1.7) XTOL2 Phase 3 efficacy data and medical education
Revenue
$
Diluted EPS
$-1.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Xenon Pharmaceuticals Inc. (XENE) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Confident tone AZK Phase 3 Data & Regulatory Submission Commercial Launch Preparation Early-Stage Pain Pipeline
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-22
Xenon Pharmaceuticals Inc. (XENE) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-09
Xenon Pharmaceuticals Inc. (XENE) Q4 2025 Earnings Call
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Confident tone Azetukalner differentiation and commercial profile X-TOLE2 Phase III readout in focal onset seizures Earlier-stage ion channel programs (Nav1.7, Kv7, Nav1.1)
Revenue
$
Diluted EPS
$-1.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
Confident tone Azetukalner Phase III X-TOLE2 in focal onset seizures Earlier-stage Nav1.1, Nav1.7 and Kv7 pipeline Major depressive disorder (MDD) Phase III program
Revenue
$
Diluted EPS
$-1.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
Positive tone Azetukalner Phase 3 epilepsy (X-TOLE2) Investigator-led MDD study results Azetukalner in MDD and bipolar depression
Revenue
$7.50M
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
Confident tone Phase 3 epilepsy readout / azetukalner MDD (major depressive disorder) program Bipolar depression program
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
Confident tone Azetukalner epilepsy program (X-TOLE) Nav1.7 pain program MDD program (X-NOVA)
Revenue
$
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Xenon Pharmaceuticals Inc. (XENE) Q2 2024 Earnings Call Transcript
Confident tone Phase 3 azetukalner epilepsy program execution Nav1.7 sodium channel pain program X-ACKT primary generalized tonic-clonic seizure study
Revenue
$
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Call Transcript
Confident tone Azetukalner (XEN1101) INN naming milestone Phase III epilepsy program (X-TOLE2, X-TOLE3, X-ACKT) Kv7 pipeline and discovery portfolio
Revenue
$
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
Confident tone XEN1101 Phase 3 Epilepsy Program (X-TOLE2/X-TOLE3/X-ACKT) MDD Development / X-NOVA Results FDA End-of-Phase 2 Meeting
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Xenon Pharmaceuticals Inc. (XENE) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2022 Earnings Call Transcript
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Earnings Call Transcript
Revenue
$132,000
▼ 98.4% YoY
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Xenon Pharmaceuticals Inc. (XENE) Q2 2022 Earnings Call Transcript
Revenue
$536,000
▼ 75.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Xenon Pharmaceuticals Inc. (XENE) Q1 2022 Earnings Call Transcript
Revenue
$8.77M
▲ 101.1% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2021 Earnings Call Transcript
Revenue
$3.74M*
▼ 27.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Xenon Pharmaceuticals Inc. (XENE) Q3 2021 Earnings Call Transcript
Revenue
$8.12M
▲ 24% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Xenon Pharmaceuticals Inc. (XENE) Q2 2021 Earnings Call Transcript
Revenue
$2.22M
▼ 83.4% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Xenon Pharmaceuticals Inc. (XENE) Q1 2021 Earnings Call Transcript
Revenue
$4.36M
▼ 38.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Xenon Pharmaceuticals Inc. (XENE) Q4 2020 Earnings Call Transcript
Revenue
$5.15M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Xenon Pharmaceuticals Inc. (XENE) Q3 2020 Earnings Call Transcript
Revenue
$6.55M
▲ 87.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Xenon Pharmaceuticals Inc. (XENE) Q2 2020 Earnings Call Transcript
Revenue
$13.38M
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-21
Xenon Pharmaceuticals Inc. (XENE) Q1 2020 Earnings Call Transcript
Revenue
$7.08M
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-09
Xenon Pharmaceuticals Inc. (XENE) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1582313 CUSIP 98420N105 13F (30d) 7 filings 7 filers Visit website Investor relations